Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23597147)

1.

Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion.

Shah AA, Schiopu E, Hummers LK, Wade M, Phillips K, Anderson C, Wise R, Boin F, Seibold JR, Wigley F, Rollins KD.

Arthritis Res Ther. 2013 Apr 18;15(2):R54. doi: 10.1186/ar4216.

PMID:
23597147
2.

Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.

Jones A, Wang-Smith L, Pham T, Laliberte K.

J Cardiovasc Pharmacol. 2014 Mar;63(3):227-32. doi: 10.1097/FJC.0000000000000039.

PMID:
24603117
3.

Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.

White RJ, Torres F, Allen R, Jerjes C, Pulido T, Yehle D, Howell M, Laliberte K, Marier JF, Tapson VF.

J Cardiovasc Pharmacol. 2013 Jun;61(6):474-81. doi: 10.1097/FJC.0b013e31828685da.

PMID:
23328389
4.

Cutaneous iontophoresis of treprostinil in systemic sclerosis: a proof-of-concept study.

Roustit M, Gaillard-Bigot F, Blaise S, Stanke-Labesque F, Cracowski C, Seinturier C, Jourdil JF, Imbert B, Carpentier PH, Cracowski JL.

Clin Pharmacol Ther. 2014 Apr;95(4):439-45. doi: 10.1038/clpt.2013.255. Epub 2014 Jan 23.

PMID:
24458011
5.

Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis.

Jenkins A, Wang-Smith L, Marbury T, Laliberte K.

J Cardiovasc Pharmacol. 2013 Apr;61(4):272-6. doi: 10.1097/FJC.0b013e31827e0fa9.

PMID:
23188123
6.

The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers.

Lim A, Wang-Smith L, Kates J, Laurent A, Kumar P, Laliberte K.

J Clin Pharm Ther. 2013 Dec;38(6):450-5. doi: 10.1111/jcpt.12085. Epub 2013 Aug 8.

PMID:
23927483
7.

Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.

Wade M, Baker FJ, Roscigno R, DellaMaestra W, Arneson CP, Hunt TL, Lai AA.

J Clin Pharmacol. 2004 May;44(5):503-9.

PMID:
15102871
8.

An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.

Peterson L, Marbury T, Marier J, Laliberte K.

J Clin Pharm Ther. 2013 Dec;38(6):518-23. doi: 10.1111/jcpt.12094. Epub 2013 Aug 28.

PMID:
24033615
9.

Cathodal iontophoresis of treprostinil induces a sustained increase in cutaneous blood flux in healthy volunteers.

Blaise S, Roustit M, Hellmann M, Millet C, Cracowski JL.

J Clin Pharmacol. 2013 Jan;53(1):58-66. doi: 10.1177/0091270011434352. Epub 2013 Jan 24.

PMID:
23400744
10.

Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.

Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K.

J Clin Pharmacol. 2010 Jul;50(7):829-34. doi: 10.1177/0091270009351173. Epub 2010 Feb 4.

PMID:
20133511
11.

Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.

J Rheumatol. 1992 Sep;19(9):1407-14.

PMID:
1279170
12.

Treprostinil for the treatment of severe digital necrosis in systemic sclerosis.

Engel G, Rockson SG.

Vasc Med. 2005 Feb;10(1):29-32.

PMID:
15920997
13.

Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.

McSwain CS, Benza R, Shapiro S, Hill N, Schilz R, Elliott CG, Zwicke DL, Oudiz RJ, Staszewski JP, Arneson CP, Wade M, Zaccardelli D, McLaughlin V.

J Clin Pharmacol. 2008 Jan;48(1):19-25.

PMID:
18094217
14.

Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats.

Blaise S, Roustit M, Millet C, Ribuot C, Boutonnat J, Cracowski JL.

Br J Pharmacol. 2011 Feb;162(3):557-65. doi: 10.1111/j.1476-5381.2010.01045.x.

15.

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

Oudiz RJ, Schilz RJ, Barst RJ, GaliƩ N, Rich S, Rubin LJ, Simonneau G; Treprostinil Study Group.

Chest. 2004 Aug;126(2):420-7.

PMID:
15302727
16.

The role of treprostinil in the management of pulmonary hypertension.

Skoro-Sajer N, Lang I.

Am J Cardiovasc Drugs. 2008;8(4):213-7.

PMID:
18690755
17.

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.

Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ; FREEDOM-C2 Study Team.

Chest. 2013 Sep;144(3):952-8. doi: 10.1378/chest.12-2875.

PMID:
23669822
18.

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.

Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ.

Circulation. 2013 Feb 5;127(5):624-33. doi: 10.1161/CIRCULATIONAHA.112.124388. Epub 2013 Jan 10.

19.
20.

Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.

Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin LJ.

Cardiovasc Ther. 2013 Feb;31(1):38-44. doi: 10.1111/1755-5922.12008.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk